|
| 非小细胞肺癌的EGFR靶向治疗进展 |
| Advances in EGFR- Targeted Therapy for Non-Small Cell Lung Cancer |
| 投稿时间：2023-09-29 修订日期：2023-12-31 |
| DOI： |
|
 |
| 中文关键词: 非小细胞肺癌 表皮生长因子受体－酪氨酸激酶抑制剂 耐药机制 全程管理 靶向治疗 新辅助治疗 辅助治疗 晚期 |
| 英文关键词:non-small cell lung cancer epidermal growth factor receptor-tyrosine Kinase inhibitors drug resistance mechanism whole-process management targeted therapy neoadjuvant therapy adjuvant therapy advanced-stage |
| 基金项目: |
|
| 摘要点击次数: 147 |
| 全文下载次数: 10 |
| 中文摘要: |
| 以表皮生长因子受体-酪氨酸激酶抑制剂（epidermal growth factor receptor, EGFR-TKIs）为代表的靶向治疗药物已显著改善非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的预后。随着肿瘤全程管理的推进，逐渐有研究展开探讨EGFR-TKIs在新辅助治疗、辅助治疗及晚期一线治疗（EGFR-TKIs单药治疗和联合化疗、抗血管生成治疗及免疫治疗）中的疗效。而EGFR-TKIs耐药成为靶向治疗无法避免的问题，导致耐药后的治疗陷入瓶颈。本文就EGFR-TKIs的临床应用、耐药机制及抗耐药治疗进行综述。 |
| 英文摘要: |
| Targeted therapy drugs represented by epidermal growth factor receptor-tyrosine Kinase inhibitors (EGFR-TKIs) have significantly improved the prognosis of patients with non-small cell lung cancer (NSCLC). With the advancement of comprehensive tumor management, research has increasingly explored the efficacy of EGFR-TKIs in neoadjuvant therapy, adjuvant therapy and first-line treatment for advanced-stage (including EGFR-TKIs monotherapy and combined with chemotherapy, anti-angiogenesis treatment and immunotherapy). However, resistance to EGFR-TKIs has become an inevitable challenge in targeted therapy, leading to a bottleneck in post-resistance treatment. This article provides a comprehensive review on the clinical application of EGFR-TKIs, resistance mechanisms and anti-resistance treatments. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |